Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration

Table 1

Ranibizumab-related adverse events followed 24-month study period.

Adverse Events at 24 months	Sham injection	Group 0.3 mg	Group 0.5 mg
Endopnthalmitis	0%	0.8%	1.3%
Uveitis	0%	1.3%	1.3%
Rhegmatogenous retinal detachment	0.4%	0%	0%
Retinal tear	0%	0.4%	0.4%
Vitreous hemorrhage	0.8%	0.4%	0.4%
Lens damage	0%	0%	0.4%
Most severe ocular inflammation
none	87.3	83.2%	79.1%
trace	10.2	8.0%	14.6%
1+	2.5%	5.9%	3.3%
2+	0	0.8%	0.8%
3+	0	0.8%	0.8%
4+	0	1.3%	1.3%
Nonocular adverse events
Arterial hypertension	16.1	17.2%	16.3%
Myocardial infarction	1.7%	2.5%	1.3%
Stroke	0.8%	1.3%	2.5%
Non ocular hemorrhage	5.5%	9.2%	8.8%